Peripheral neuropathy developed in a considerable proportion of momelotinib-treated patients, thus limiting further the potential clinical use of the compound.29 Altogether, advancements in our understanding of the molecular pathogenesis of myeloproliferative disorders, with activation of the JAK/STAT pathway being a common denominator, has led to the development of several JAK-targeted therapies with significant effectiveness and balanced efficacy/safety risk ratio. Here, SOAT1 is linked to myeloproliferative disorder.